Skip to main content
Equibles
NMTC logo

NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp · Earnings Call Transcripts & Audio

Track NMTC — free

Use NMTC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NMTC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.53 -0.03 (-2.24%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$14.20M
Shares
9.11M

NEUROONE MEDICAL TECHNOLOGIES Corp Earnings Call Transcripts

Quarterly earnings calls for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲100.6% $36,584 −$3.06M '22 Q2 22-05-12 ▼20.1% $32,049 −$2.76M '22 Q3 22-08-11 ▲239.5% $114,579 −$1.73M '23 Q1 23-02-14 ▲1174.3% $466,176 −$3.52M '23 Q2 23-05-11 ▲1865.4% $629,906 −$3.47M '23 Q3 23-08-14 ▲753.3% $977,649 −$3.34M '24 Q1 24-02-13 ▲195.4% $1.38M −$2.86M '24 Q2 24-05-14 ▲31.1% $825,776 −$2.77M '24 Q3 24-08-14 ▼63.3% $272,284 −$3.35M '24 Q4 24-12-17 ▲234.9% $3.27M $1.79M '25 Q1 25-02-12 ▲0.7% $1.39M −$2.27M '25 Q2 25-05-13 ▲105.4% $1.70M −$1.50M '25 Q3 25-08-14 ▲906.6% $2.74M −$1.62M '25 Q4 25-12-17 ▼11.7% $2.89M −$1.44M '26 Q1 26-02-17 ▲34.3% $1.86M −$2.38M '26 Q2 26-05-12 LATEST ▲16.3% $1.97M −$2.01M '26 Q3 26-08-13
Conference
Investor event
2026-09-09
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-08-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2026 Earnings Call Transcript
Positive tone Revenue growth and order backlog Manufacturing capacity constraints and supply chain International expansion via ISO 13485 certification
Revenue
$1.97M
▲ 16.3% YoY
Diluted EPS
$-0.28
Gross margin
59.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-05-12
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2026 Earnings Call Transcript
Confident tone Trigeminal Nerve Ablation System International Expansion / ISO 13485 1RF Brain Ablation Revenue Growth
Revenue
$1.86M
▲ 34.3% YoY
Diluted EPS
$-0.28
Gross margin
53.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-02-17
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2026 Earnings Call Transcript
Confident tone 1RF brain ablation system adoption Fiscal 2026 revenue guidance Strategic partnership / licensing discussions
Revenue
$2.89M
▼ 11.7% YoY
Diluted EPS
$-0.18
▼ 150% YoY
Gross margin
54.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-12-17
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q4 2025 Earnings Call Transcript
Confident tone OneRF Brain Ablation Commercialization with Zimmer Biomet Spinal Cord Stimulation / Pain Management Financial Performance FY2025
Revenue
$2.74M*
▲ 906.6% YoY
Gross margin
55.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-08-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2025 Earnings Call Transcript
Confident tone OneRF ablation system and patient outcomes Revenue growth and guidance Intellectual property and regulatory
Revenue
$1.70M
▲ 105.4% YoY
Diluted EPS
$-0.19
Gross margin
53.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-05-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2025 Earnings Call Transcript
Confident tone OneRF Ablation System Commercial Traction Revenue Growth and FY2025 Guidance Trigeminal Nerve Ablation 510(k) Submission
Revenue
$1.39M
▲ 0.7% YoY
Diluted EPS
$-0.44
Gross margin
55.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-02-12
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2025 Earnings Call Transcript
Confident tone OneRF Ablation System Commercialization & Clinical Results Revenue & Gross Margin Growth Zimmer Biomet Partnership
Revenue
$3.27M
▲ 234.9% YoY
Diluted EPS
$0.36
Gross margin
58.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-17
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q4 2024 Earnings Call Transcript
Confident tone OneRF Ablation System commercial launch Zimmer Biomet partnership expansion Fiscal 2025 financial guidance
Revenue
$272,284*
▼ 63.3% YoY
Gross margin
51.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-08-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2024 Earnings Call Transcript
Confident tone Revenue and Operating Results OneRF Ablation System Commercial Launch Capital and Balance Sheet
Revenue
$825,776
▲ 31.1% YoY
Diluted EPS
$-0.60
Gross margin
34.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-05-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2024 Earnings Call Transcript
Confident tone Revenue and operating results Evo sEEG commercialization with Zimmer Biomet Liquidity and capital position
Revenue
$1.38M
▲ 195.4% YoY
Diluted EPS
$-0.66
Gross margin
28.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-02-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2024 Earnings Call Transcript
Positive tone CEO Absence and Operational Continuity OneRF Ablation System FDA Clearance and Launch OneRF Pain Applications
Revenue
$977,649
▲ 753.3% YoY
Diluted EPS
$-0.84
Gross margin
27.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-08-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2023 Earnings Call Transcript
Revenue
$629,906
▲ 1865.4% YoY
Diluted EPS
$-1.20
Gross margin
38.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-05-11
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2023 Earnings Call Transcript
Revenue
$466,176
▲ 1174.3% YoY
Diluted EPS
$-1.26
Gross margin
6.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-02-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2023 Earnings Call Transcript
Revenue
$114,579
▲ 239.5% YoY
Diluted EPS
$-0.66
Gross margin
-10.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q3
2022-08-11
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2022 Earnings Call Transcript
Revenue
$32,049
▼ 20.1% YoY
Diluted EPS
$-1.02
Gross margin
-20.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-05-12
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q2 2022 Earnings Call Transcript
Revenue
$36,584
▲ 100.6% YoY
Diluted EPS
$-1.14
Gross margin
-99.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-02-14
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q1 2022 Earnings Call Transcript
Revenue
$33,748
▼ 52.8% YoY
Diluted EPS
$-1.08
Gross margin
-38.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-15
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q4 2021 Earnings Call Transcript
Revenue
$48,336*
Gross margin
-35.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-08-13
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Q3 2021 Earnings Call Transcript
Revenue
$40,096
Diluted EPS
$-1.50
Gross margin
-54.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts CIK 1500198 CUSIP 64130M308 13F (30d) 1 filings 1 filers Visit website Investor relations